BioSpace News Archive

Last December 25, the anti-tumor drug candidate Chiauranib, developed by Shenzhen Chipscreen Biosciences Co., Ltd., was granted with the “Breakthrough Therapy Designation Drug” by the Center for Drug Evaluation and currently enter a phase III clinical trial for treatment of patients with small cell lung cancer with disease progression or recurrence after two lines of prior systematic chemotherapy.

IDEAYA Biosciences, Inc., an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics, announced First-Patient-In in the Phase 1 combination study of IDE196 and crizotinib, a cMET inhibitor, in metastatic uveal melanoma.

Biodesix, Inc., a leading data-driven diagnostic solutions company with a focus in lung disease, announced that Ryan Siurek has joined the company as Chief Accounting Officer reporting to Ms. Robin Harper Cowie, Chief Financial Officer.

G1 Therapeutics, Inc., a clinical-stage oncology company, announced that Chief Executive Officer Jack Bailey will present a company update at the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021 at 2:50 p.m. ET.

iTeos Therapeutics, Inc. announced that Michel Detheux, PhD, President and Chief Executive Officer, will present a company overview at the 39th Annual J.P. Morgan Conference, being held virtually on Tuesday, January 12, 2021 at 9:10 a.m. ET.

Orchard Therapeutics, a global gene therapy leader, announced that the company is scheduled to present at the 39th Annual J.P. Morgan Healthcare Conference being held virtually on Wednesday January 13, 2021 at 9:10 AM ET.

Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism to treat cancer and genetically defined diseases, announced that the company is scheduled to present at the virtual 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021 at 10:50 a.m. ET.

Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that ORGOVYX™ (relugolix), the first and only oral gonadotropin-releasing hormone (GnRH) receptor antagonist approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with advanced prostate cancer, is now available through authorized specialty distributors. “Myovant has been focused on ens

Sutro Biopharma, Inc. announced that Bill Newell, Chief Executive Officer, will present at the 39th Annual J.P. Morgan Virtual Healthcare Conference on Thursday, Jan. 14, 2021 at 5:20 p.m. ET / 2:20 p.m. PT.

Sierra Oncology, Inc. announced that President and Chief Executive Officer Stephen Dilly, MBBS, PhD, will present an overview of the company at the H.C. Wainwright 2021 BioConnect Virtual Conference taking place January 11-14, 2021.